Toxic Epidermal Necrolysis: A Clinical and Therapeutic Review

Toxic Epidermal Necrolysis is a rare dermatological condition with high mortality and serious consequences on its survivors. Despite having been first described in 1956, pathophysiology remains uncertain, mainly regarding mechanisms, although it seems that certain apoptosis pathways are pivotal starting keratinocytes’ activating T cells, especially those mediated by tumour necrosis factor, Fas-FasL granulysin. In general, aetiology presentation consensual, being defined as generalized necrolysis of the epidermis occurs an uncontrolled immune response to specific drug or one metabolites, highlighting cotrimoxazole allopurinol most important. This leads massive shedding epidermal layer skin, stronger incidences torso, upper limbs face. Its complications tend be severe, noting septic ones responsible for over half disease’s mortality. Nearly all survivors develop long-term sequelae, namely hypertrophic scarring skin pigmentation anomalies. Regarding treatment, many different opinions arise, including contradictory ones, more importantly immunomodulation therapies have focus several studies through years. It safe state supportive therapy only modality has significantly strong evidence backing efficacy reducing improving prognosis, which improved past years general health care quality increased. conclusion, imperative say research needed new potential large study populations scientific rigor. Likewise, investigation towards basic should also promoted, at biomolecular level, allowing prevention this illness.